摘要
分子生物学的深入探讨使自然杀伤细胞(natural killer cell,NK cell)在肿瘤发生发展过程中的作用重新被人们所认识;NK细胞的扩增作为免疫治疗的手段又开始受到人们的重视。以往,虽然证明NK细胞的过继免疫治疗是安全的,但自体NK细胞过继免疫治疗的临床疗效却不能令人满意。新近的研究发现,通过靶向药物单克隆抗体的协同,可以明显改善其抗肿瘤效果。对NK细胞表面受体的研究证明抑制性受体KIR在逃避免疫中起了重要作用,而抑制这些受体能够明显提高NK细胞的杀伤效率,为临床应用提供了可靠的理论基础和实际应用的可行性。异体半相合NK细胞的临床应用有可能克服自身NK细胞的缺陷,而对细胞信号进行靶向调节是最重要的突破,将进一步为临床广泛应用提供了可能。本文就NK细胞过继免疫治疗的最新进展作一综述。
As it is discovered that NK cell disfunction is related to the ocurrance and development of cancer,the adoptive transfer of NK cells has been widely studied in various clinical trials to treat cancer.According to the source of NK cells in these clinical trials,the adoptive transfer is classified into autologous NK cell adoptive transfer and allogeneic NK cell adoptive transfer.The adoptive transfer is safe in these trials,but not of evident clinical benefit.Some of the trials show that allogeneic NK cell adoptive transfer acts better than autologous NK cell adoptive transfer.To improve the clinical benefit of NK cell adoptive transfer,it is important to strengthen the recognition and killing ability of NK cell to cancer cell.Some methods are proved to be effective.This article will make a retrospect on the clinical trials of NK cell adoptive transfer.
出处
《临床肿瘤学杂志》
CAS
2010年第4期380-383,共4页
Chinese Clinical Oncology
